ROY BASCOM SMITH, M.D.
Medical Practice at Fannin St, Houston, TX

6682908, Jan 27, 2004

Jun 13, 2001

09/743475

Roy G. Smith - Houston TX
Leonardus H. T. Van der Ploeg - Scotch Plains NJ
Andrew D. Howard - Park Ridge NJ
Hui Zheng - Houston TX
Karen Kulju McKee - Middletown NJ
Michael M. Jiang - Edison NJ

Merck Co., Inc. - Rahway NJ

C12N 510

435 691, 435 711, 4353201, 435471, 4352523, 435325, 530351, 536 235

A mouse growth hormone secretagogue receptor has been isolated, cloned and sequenced. This receptor is characteristic of the G-protein family of receptors. Mouse growth hormone secretagogue receptors may be used to screen and identify compoumds which bind to the mouse growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and those recovering from hip fracture and osteoporosis. Targeted disruption of the mouse GHS-R gene may prove useful in elucidation of the mechanism of action and role of the growth hormone secretagogues in human and animal physiology.

2005026, Nov 24, 2005

Mar 30, 2005

11/094339

William Polvino - Tinton Falls NJ, US
David Carpi - Somerset NJ, US
Roy Smith - Houston TX, US

Rejuvenon Corporation - Bridgewater NJ

A61K038/05, A61K031/454

514018000, 514323000

The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke (such as transient ischemic attacks (TIAs)). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be coadministered with a second growth hormone secretagogue, HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a Beta blocker, a cholesterol absorption inhibitor, a nicotonic acid, a fibric acid derivative, a bile acid sequestering agent or a combination thereof.

4145168, Mar 20, 1979

Nov 12, 1976

5/741505

Roy H. Smith - Houston TX
Bobby J. Travis - Vidor TX

F01C 108, F01C 118, F01C 2100

418150

A positive displacement device utilizing at least two rotors which roll sealingly on one another at a common pitch surface speed. Outwardly extending lobes on one rotor sealing engage the cylindrical bore of the housing of the device, fluid traversing the device circumferentially in the annulus between such bore and the pitch surface of the rotor. Speed of rotation of the two rotors is controlled by a timing chain running between sprockets mounted on the rotor shafts. When the lobe passes the line of sealing contact, a cavity is provided in the meshing rotor, and the lobe makes sealing contact with the wall of this cavity during at least that interval when there is no sealing contact between the pitch surfaces, i. e. , the interval when the mouth of the cavity is passing through dead center. The inventor shows that the cavity is a modified path he calls the reentrant loop of an endoepicycloid, which is the path of the tip of a fixed radial extension of one circle as it rolls without slipping around the circumference of a second, fixed circle.

7179886, Feb 20, 2007

Jun 8, 1999

09/719485

Scott D. Feighner - Holmdel NJ, US
Arthur A. Patchett - Westfield NJ, US
Carina Tan - Metuchen NJ, US
Karen Kulju McKee - Middletown NJ, US
Douglas MacNeil - Westfield NJ, US
Andrew D. Howard - Park Ridge NJ, US
Roy G. Smith - Houston TX, US

Merck & Co., Inc. - Rahway NJ

G01N 33/53, C01K 14/00, C12P 21/06

530350, 435 71, 435 691, 435325, 4353201

The motilin receptor has been isolated and cloned, and nucleic acid sequences are given. Two spice variants have been identified. Also, assays for motilin receptor ligands are given. The identification of the cloned motilin receptor may be used to screen and identify compounds which bind to the receptor for use in a variety of gastric conditions, including gastric motility disorders.